Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment guidelines news

Show

From To
All-access for blockbuster TB drug in South Africa

The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

Published
19 June 2018
From
Health-e
Starting HIV treatment at diagnosis slashes drop out, drug failure rates, China study finds

Patients diagnosed with HIV who started antiretroviral treatment within 30 days had significantly lower rates of dropping out of treatment, and higher rates successful treatment, than those who started later, particularly those who started more than three months after their diagnosis, a study in China has found.

Published
04 June 2018
From
Science Speaks
South Africa: Birth defects fears prompt warnings about new ARV

Despite the public concern globally, very little has been said about the impact of the safety warning about dolutegravir on South Africa, the country with the largest HIV treatment programme in the world. The National Department of Health had already planned to introduce a dolutegravir-based first line regimen to replace the existing regimen, hoping to switch the majority of patients starting from last month.

Published
29 May 2018
From
Health-e
HIV Care Gaps of Less Than 9 Months Do Not Worsen Patients

Gaps in care of up to 9 months for patients with HIV do not worsen viral loads, a study involving more than 6000 HIV-infected individuals has found. Current guidelines specify that gaps in visits to primary care doctors should not exceed 6 months for clinically stable HIV patients with sustained viral suppression—even though longer lapses are common.

Published
16 May 2018
From
MD Magazine
Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

Phase 3 randomised trials for drug approval in high-income countries do not provide sufficient evidence to support the widespread use of new antiretrovirals in low- and middle-income countries (LMICs), where the majority of people with HIV live. Key missing evidence is typically for pregnant women, people with HIV/TB coinfection and people who have not had resistance testing before starting ART.

Published
15 May 2018
From
HIV i-Base
Computer Models Are Changing How We Craft HIV-AIDS Policies

A computer modeling of AIDS-affected populations of sub-Saharan Africa has recently enabled the World Health Organization (WHO) to identify a cost-effective measure to address the increasing prevalence of drug-resistant HIV in the region.

Published
04 May 2018
From
Healthcare Analytics News
NHS England saved £10 million by switching to generic anti-HIV drugs in 2016

A programme to encourage clinicians to switch people to generic antiretroviral drugs saved the NHS almost £10 million in the financial year 2016-2017, Dr Laura

Published
30 April 2018
By
Roger Pebody
Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices — But Really 2 Are Best

With the important caveat that what follows represents my opinion and not that of these or any other guidelines, one could easily argue that there are really two primary choices here, not five.

Published
23 April 2018
From
NEJM Journal Watch
India could shift from efavirenz to dolutegravir for HIV treatment – at no extra cost, new research suggests

Researchers recommend dolutegravir (DTG)‐based antiretrovirals should become the first option for HIV treatment in India, following a study into DTG’s cost-effectiveness.

Published
13 April 2018
From
Avert
ARV stock-outs kill more Ugandans

“Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

Published
12 April 2018
From
The Observer
← First12345...36Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.